Compared to other industries, the pharmaceuticals sector has
been slow to promulgate guidelines with respect to social media.
But, recent cases have begun to stoke the flames that guidelines
are imminent and necessary. The recent case of the FDA
cracking down on Novartis is a perfect illustration. Novartis
had used Facebook and ShareThis, two popular social networking
sites, to influence consumers in spreading the word about Tasigna,
a cancer drug. The FDA concluded that Novartis' act failed to
meet regulatory and compliance standards. Specifically, the
FDA called out Novartis' marketing as incomplete and misleading
since it failed to communicate any risk information associated with
the use of Tasigna.
Download the "Social
Media and the Pharmaceuticals Industry" white paper
The Actiance Platform
Our solutions for pharmaceutical firms include:
- Social Media Compliance
- Pre-review moderation of content
- Log and record online conversations in context
- Archive content for FDA compliance
- Social Media Enablement
- Share relevant & pre-approved content
- Ensure authenticity of voice
- Measure impact and increase engagement
- Social Media & Web 2.0 Security
- Granular control over use and access of features
- Malware prevention
- Instant Messaging Compliance
- Monitor and archive IM conversations
- Unified Communications Security & Compliance
- Implement ethical walls
- Log and record conversations in context
- Archive content for FDA compliance
Contact our team
today to find out how we can help you.